> Research Use Only (RUO) Disclaimer: AICAR (acadesine) is an investigational compound used exclusively in preclinical and laboratory research contexts. It has not been approved by the FDA or any regulatory authority for human use, therapeutic applications, or diagnostic purposes. The dosage parameters and protocols described in this guide are drawn from published scientific literature on animal and in vitro studies. This content is provided for educational and research reference purposes only and does not constitute medical advice. Researchers must comply with all applicable local, state, and federal regulations governing research compound use.
# AICAR Dosage Protocol Guide: AMPK Activator Reconstitution & Metabolic Research (2026)
AICAR — 5-aminoimidazole-4-carboxamide ribonucleotide — is among the most studied AMPK-activating compounds in metabolic research. Since the landmark 2008 Cell paper by Narkar et al. demonstrated that AICAR alone could increase running endurance in sedentary mice by 44%, it has anchored a generation of research into metabolic reprogramming, mitochondrial biogenesis, and what the popular press labeled "exercise in a bottle."
This guide consolidates what the published literature tells us about AICAR reconstitution, storage, research dosing, administration routes, and its position relative to other AMPK-pathway tools — so researchers can design experiments with an accurate reference baseline.
---
What Is AICAR? Mechanism in Brief
AICAR is a cell-permeable nucleoside analog. Once inside the cell, it is phosphorylated to ZMP (AICAR monophosphate), which structurally mimics AMP. Because ZMP accumulates without raising actual AMP levels, it activates the γ-subunit of AMPK by mimicking a high-energy-deficit signal — the same signal that normally fires during prolonged exercise.
Core downstream effects studied in research:
| Pathway | Effect | Primary Evidence |
|---|---|---|
| PGC-1α upregulation | Mitochondrial biogenesis | Narkar et al., 2008; Winder et al., 2000 |
| GLUT4 translocation | Skeletal muscle glucose uptake | Bergeron et al., 2001 |
| Fatty acid oxidation | β-oxidation enzyme activity | Merrill et al., 1997 |
| mTORC1 inhibition | Protein synthesis modulation | Inoki et al., 2003 |
| ULK1 phosphorylation | Autophagy induction | Kim et al., 2011 |
Because AICAR activates AMPK upstream of all these pathways, it has become a standard pharmacological tool for studying energy-sensing biology — not just in muscle, but in liver, adipose tissue, cardiac muscle, and neurons.
---
Research Applications
Endurance and Exercise Mimicry
The defining study remains Narkar VA et al., Cell 2008 (PMID: 18674809). In sedentary mice given AICAR (500 mg/kg/day × 4 weeks, intraperitoneal), treadmill running distance increased 44% vs. controls. Critically, this occurred without any exercise training, establishing AICAR as an exercise mimetic rather than a performance enhancer contingent on training.
When combined with the PPARδ agonist GW-501516, effects were additive (GW-501516 alone: +68% endurance; combined: +77%). However, GW-501516 is NOT available in the Peptides.SO library due to its carcinogenicity profile in long-term animal studies. Researchers interested in the PPARδ axis should note this constraint.
Metabolic Syndrome Models
AICAR has been studied extensively in diet-induced obesity (DIO) rodent models. Research findings include:
- •Reduction in hepatic lipid accumulation via AMPK-mediated inhibition of fatty acid synthase (FASN)
- •Improved insulin sensitivity in insulin-resistant skeletal muscle
- •Attenuation of hepatic glucose production through TORC2/CREB pathway suppression
Mitochondrial Biogenesis
AICAR drives mitochondrial biogenesis primarily through PGC-1α, the "master regulator" of mitochondrial content. Studies in both skeletal and cardiac muscle show increased citrate synthase activity and mitochondrial DNA copy number following sustained AICAR treatment. This pathway overlaps with that studied under MOTS-c research — the MOTS-c dosage protocol guide covers the mitochondria-derived peptide side of the same signaling biology.
Cardioprotection
AICAR has a separate line of research as "acadesine" in cardioprotection. The compound was investigated in clinical trials (DIANA trial, 2003) for reducing perioperative cardiac events during coronary artery bypass graft surgery. While results were mixed at the clinical level, the mechanistic interest in AICAR's cardiac energy-stabilizing effects remains active.
---
The Narkar 2008 Landmark Study — Design Details
Full citation: Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM. "AMPK and PPARdelta agonists are exercise mimetics." Cell. 2008 Aug 8;134(3):405-15. PMID: 18674809.
Relevance to researchers: This study is the primary source cited for AICAR endurance research protocols. Key design parameters:
- •Species: C57BL/6 mice, 4–5 weeks old, male
- •AICAR dose: 500 mg/kg/day
- •Route: Intraperitoneal (IP)
- •Duration: 4 weeks
- •Vehicle: Sterile saline (0.9% NaCl)
- •Outcome measure: Treadmill exhaustion test (Columbus Instruments)
- •Controls: Vehicle-injected sedentary mice
The 500 mg/kg/day dose is a high pharmacological load. Researchers designing experiments should note that lower doses (50–250 mg/kg) have been used in subsequent studies focused on metabolic rather than endurance endpoints.
---
Reconstitution Protocol
AICAR is water-soluble. Standard laboratory reconstitution uses bacteriostatic water (BAC water) for multi-dose vials, or sterile saline for single-use preparations.
Step-by-Step Reconstitution
1. Determine target concentration. For in vivo studies replicating Narkar et al., a common working concentration is 50 mg/mL to allow reasonable injection volumes.
2. Allow lyophilized powder to reach room temperature before opening (prevents condensation from contaminating the vial).
3. Inject solvent slowly down the side of the vial — do not force directly onto the lyophilized cake.
4. Gently swirl (do not vortex or shake) until fully dissolved. AICAR dissolves readily; clear solution within 30–60 seconds is expected.
5. Inspect for clarity. The solution should be colorless to pale yellow and free of particulates.
6. Filter if needed for sterile preparations (0.22 µm syringe filter recommended for in vivo use).
Solvent Options
| Solvent | Use case | Notes |
|---|---|---|
| Bacteriostatic water (BAC) | Multi-dose vials | 28-day stability after reconstitution |
| Sterile 0.9% NaCl | Single-dose/acute studies | Prepare fresh |
| PBS (pH 7.4) | Cell culture / in vitro | No preservative needed |
| DMSO (low %) | Very concentrated stocks only | Dilute to <1% DMSO for in vivo |
---
Storage
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (dry) | −20°C | ≥2 years (manufacturer-specified) |
| Reconstituted (BAC water) | 4°C | Up to 28 days |
| Reconstituted (sterile saline) | 4°C | Use within 5–7 days |
| Reconstituted (frozen) | −80°C | 6–12 months, avoid repeated freeze-thaw |
Protect from light. While AICAR is not highly photosensitive, amber vials or foil wrapping during storage are standard practice.
---
Research Dosing Parameters from Literature
The following dose ranges come from published studies and represent the range used in animal research only. No human dosing data exists from controlled trials targeting metabolic/endurance endpoints.
Rodent Studies (Published Range)
| Research Endpoint | Dose (mg/kg/day) | Route | Duration | Reference |
|---|---|---|---|---|
| Endurance/exercise mimicry | 500 | IP | 4 weeks | Narkar et al., 2008 |
| Skeletal muscle GLUT4 | 250–500 | IP | Acute (1–4h) | Kurth-Kraczek et al., 1999 |
| Hepatic lipid reduction | 250 | IP | 4 weeks | Pencek et al., 2003 |
| Mitochondrial biogenesis | 500 | IP | 5 weeks | Winder et al., 2000 |
| Cardiac protection | 10–50 | IV infusion | Acute peri-operative | Mangano et al., 2002 |
Important Research Notes
- •High dose / short duration vs. lower dose / longer duration: Most endurance studies use the high-dose acute model. Chronic metabolic studies sometimes use lower doses (250 mg/kg) to limit off-target effects.
- •Vehicle matching: Always include a vehicle-injected control group receiving equivalent volume.
- •ZMP accumulation: AICAR's active intracellular form (ZMP) can accumulate to supra-physiological levels; this is pharmacologically useful but should be monitored in study designs examining downstream signaling specificity.
- •WADA status: AICAR was added to the WADA prohibited list in 2011 (S4 — Hormone and Metabolic Modulators). This is relevant context for sports-doping research but does not affect laboratory preclinical use.
---
Administration Routes in Research
Intraperitoneal (IP) — Most Common
Used in the majority of published rodent studies. Rapid absorption, reproducible pharmacokinetics. Standard for replicating published metabolic and endurance protocols.
Intravenous (IV) — Cardiac/Acute Studies
Used in cardiac protection research (e.g., DIANA trial). Allows precise dose titration and rapid onset. Used for acute surgical/ischemia-reperfusion models.
Subcutaneous (SC)
Less commonly used. Absorption is slower and more variable than IP. Some chronic metabolic studies have used SC to avoid repeated IP injections in long-term protocols.
Oral / Intragastric Gavage
Limited data. AICAR has poor oral bioavailability due to first-pass metabolism and is generally not used via oral route in rodent studies. Not a standard administration route for replicating published protocols.
In Vitro / Cell Culture
AICAR is widely used in cell culture at concentrations of 0.1–2 mM for 1–24 hours to activate AMPK in isolated cells. Cell culture is the most common use context for mechanism studies.
---
AICAR vs. Other AMPK Research Tools
AICAR vs. MOTS-c
MOTS-c is a mitochondria-derived peptide that also activates AMPK — but through a distinct upstream mechanism. Where AICAR mimics AMP directly, MOTS-c appears to work through folate-cycle intermediates that influence the AMP:ATP ratio. Researchers studying AMPK biology often use both compounds to dissect pathway specificity. See the MOTS-c dosage protocol guide for a detailed comparison.
AICAR vs. Metformin
Metformin (a biguanide pharmaceutical) activates AMPK by inhibiting complex I of the mitochondrial electron transport chain, raising AMP indirectly. AICAR bypasses this mechanism entirely by directly mimicking AMP via ZMP. This difference makes AICAR preferable for studies requiring direct AMPK activation without mitochondrial respiratory chain effects.
AICAR vs. A-769662
A-769662 is an allosteric AMPK activator that binds the β-subunit carbohydrate-binding module, activating AMPK by a different mechanism than AMP/ZMP binding. A-769662 + AICAR is a common pharmacological combination in pathway studies requiring maximal AMPK activation.
Note on GW-501516 (Cardarine)
The Narkar 2008 study used AICAR in combination with GW-501516, a PPARδ agonist, to achieve additive endurance effects. GW-501516 is not available in the Peptides.SO library and is not recommended for research use due to carcinogenicity findings in long-term animal studies (tumor formation at multiple sites in 2-year rat studies). Researchers should not substitute GW-501516 for other PPARδ tools without reviewing this safety literature.
---
Safety Considerations in Research Context
AICAR has a well-characterized safety profile in preclinical research at doses used in published studies:
- •Hypoglycemia risk at high doses: High-dose AICAR increases peripheral glucose uptake; blood glucose monitoring is recommended in rodent protocols involving doses ≥500 mg/kg.
- •Uric acid: AICAR's purine metabolism can increase uric acid levels; relevant in models studying gout or hyperuricemia.
- •Immune effects: AICAR has anti-inflammatory properties (NF-κB suppression via AMPK); this is pharmacologically relevant and should be accounted for in immune-challenged models.
- •No human clinical trials at metabolic/endurance doses: The human safety data from the DIANA trial used acute IV infusion at much lower doses than the 500 mg/kg rodent protocols. There are no human data supporting safety at doses equivalent to metabolic endurance studies.
This compound is strictly a research tool. It is not approved for use in humans for any indication related to metabolic enhancement, endurance, or body composition.
---
Frequently Asked Questions
Is AICAR FDA-approved?
No. AICAR (as acadesine) was investigated in clinical trials for cardiac indications but was never approved by the FDA. It is strictly a research compound for laboratory use.
What is the difference between AICAR and Acadesine?
They are the same compound. Acadesine is the INN (International Nonproprietary Name); AICAR is the biochemical abbreviation for 5-aminoimidazole-4-carboxamide ribonucleotide. Both names refer to the same molecule.
Does AICAR require refrigeration before reconstitution?
Lyophilized AICAR should be stored at −20°C. Some suppliers permit short-term (weeks) room temperature storage of sealed lyophilized vials, but −20°C is the standard for long-term stability.
Can AICAR be combined with growth hormone secretagogues in research?
In principle, combining AICAR (AMPK activation) with GH secretagogues (somatotropic axis) would engage distinct pathways and is mechanistically plausible for metabolic studies. No published combined protocols exist to guide dosing. The Best Peptides for Muscle Growth Research article covers the GH secretagogue literature separately.
How is AICAR detected by WADA?
AICAR and its metabolite ZMP are detectable in urine by LC-MS/MS. WADA added it to the prohibited list in 2011. This is sport science context, not a research limitation.
What is the read-out for AMPK activation in cell studies?
Standard read-outs are phospho-AMPK (Thr172) and phospho-ACC (Ser79) by Western blot. These are the canonical markers used in the published AICAR literature.
---
Internal Resources
- •AICAR price comparison and supplier listings — 27 active AICAR listings on Peptides.SO
- •MOTS-c dosage protocol guide — companion guide for the mitochondria-derived AMPK activator
- •Best Peptides for Muscle Growth Research — covers GH secretagogues (separate pathway from AMPK)
- •Peptide calculator — dosing and dilution tools for research preparation
---
Summary
AICAR occupies a unique position in metabolic research: it is the pharmacological gold standard for acute AMPK activation in preclinical models, with a clear mechanistic pathway (AMP mimicry via ZMP) and a landmark study that defined the exercise-mimetic research space. For researchers working in energy metabolism, mitochondrial biology, or insulin signaling, AICAR remains an essential tool.
The standard published protocol — 500 mg/kg/day IP in rodents for 4 weeks — replicates the Narkar 2008 conditions. Lower doses (250 mg/kg) serve chronic metabolic studies. Reconstitution in BAC water at 50 mg/mL is standard practice. Storage at −20°C (dry) or 4°C (reconstituted) maintains stability within expected research timelines.
All use should be within the bounds of approved institutional research protocols and applicable regulations.